CFN Media

September 19, 2017 09:00 ET

Pivot Pharma Looks to Improve Cannabinoid Bioavailability with Topical BiPhasix™ Delivery System -- CFN Media

SEATTLE, WA--(Marketwired - Sep 19, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article examining Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) and its recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids.

A major problem with cannabinoid-based therapeutics is the lack of a robust delivery mechanism. In a 2009 study, researchers found that the bioavailability varied from 2-56% for inhaled cannabis smoke to 4-20% for oral consumption. The absorption of inhaled cannabinoids tended to vary widely between individuals, while the oral consumption of cannabinoids was degraded in the stomach and subject to first-pass metabolism in the liver. In addition, smoking may not be appealing to patients for health or lifestyle reasons. Topical delivery is an alternative but current topical cannabinoid preparations suffer from many formulation issues such as weak or inert creams and poor absorption, and they are often not very consumer friendly (e.g. greasy or oily).

Transdermal cannabinoid delivery could provide a great alternative route of administration since it reduces the negative side effects associated with inhaled dosing and bypasses first-pass metabolism in the liver. In addition, transdermal delivery enables patients to access a steady stream of medication over a prolonged period of time rather than experiencing only acute effects.

Pivot Pharma Acquires BiPhasix™

Pivot Pharmaceuticals recognized the benefits of transdermal cannabinoid delivery and acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. The company's newly created subsidiary, Pivot Green Stream Health Solutions Inc. ("Pivot Green Stream"), will focus on improving bioavailability of cannabinoid-based nutraceuticals and pharmaceuticals, including treatments for female sexual dysfunction and psoriasis.

"I am pleased to lead Pivot as we continue to develop therapeutic pharmaceuticals and nutraceuticals as well as drug delivery platforms," said Interim CEO Patrick Frankham, PhD, MBA, in a recent press release announcing the new delivery system. "BiPhasix™ is a disruptive technology that will revolutionize how medical cannabinoids are administered."

BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown that it can significantly enhance the bioavailability of many drugs and improve clinical outcomes. In addition, the delivery system can serve as an alternative dosage form to injectables by providing less invasive routes of administration, such as dermal, transdermal, nasal, vaginal, ocular, and rectal.

Lead Product Candidates

PGS-N005 (Female Sexual Dysfunction CBD Topical Cream)

Using BiPhasix™ platform technology, Pivot Green Stream will initiate development of a topical cream containing CBD ("PGS-N005") for perimenopausal, menopausal and post-menopausal women who have noticed a decline in sexual desire and response, known as hypoactive sexual desire disorder (HSDD). Up to 63% of sexually active women in the U.S. might be affected by female sexual dysfunction ("FSD"). While erectile dysfunction in men has been extensively researched, very little has been completed on FSD which can involve reduced sex drive, difficulty becoming aroused, vaginal dryness, lack of orgasm and decreased sexual satisfaction. The FSD market in the U.S. is estimated to exceed $4 billion with over 50 million potential sufferers.

PGS-N007 (Psoriasis BiPhasix™ CBD Topical Cream)

The psoriasis market is set to rise from $6.6 billion in 2014 to over $13.3 billion by 2024 at a compound annual growth rate of 7.3 percent. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States. According to Global Data and the World Health Organization, the reported prevalence of psoriasis in countries ranges between 0.09% and 11.4%, making psoriasis a serious global problem with at least 100 million individuals affected worldwide.

Research has shown that CBD has potent anti-inflammatory properties suggesting that cannabinoids may be helpful for inflammation-related skin conditions like psoriasis and eczema. CBD, THC and other cannabinoids are anti-psoriasis agents. Under a psoriasis condition, skin cells are replaced every three to five days rather than the normal 30 days. This excessive and rapid growth of the epidermal layer of the skin generates red, itchy and scaly patches, which may be localized or completely cover the body. PGS-N007 will aim to treat psoriasis. 

These products (PGS-N005, PGS-N007) will be registered as 'natural health products' for consumers, which enables a shorter development cycle and faster revenue generation opportunities than traditional pharmaceuticals that tend to be much more expensive and time-consuming to develop through extensive clinical trials.

Looking Ahead

Pivot Pharmaceuticals Inc. represents a compelling opportunity in the biotechnology space. In addition to its promising pharmaceutical technology pipeline, Pivot has recently acquired a new transdermal delivery technology that it plans on immediately applying to develop cannabinoid-based products resulting in a Health Canada Natural Health Product (NHP) designation. Pivot has positioned itself in a growing and crucial vertical in the cannabis industry and will work with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

Please follow the link to read the full article:

Learn how to become a CFN Media featured company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information